Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.
Dianthus Therapeutics has raised $719.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Dianthus Therapeutics's investors include RA Capital Management, Janus Henderson Investors, Catalio Capital Management, Great Point Partners, RTW Investments.
Dianthus Therapeutics is headquartered in Waltham, United States.
Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.
Dianthus Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dianthus Therapeutics — Funding & Investors." VCBacked, March 10, 2026, https://www.vcbacked.co/company/dianthus-therapeutics. Accessed September 29, 2026.
VCBacked. (2026). Dianthus Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/dianthus-therapeutics
{{cite web |title=Dianthus Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/dianthus-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated